ArticleScientific reports2026
ALYREF-mediated RNA 5-methylcytosine modification promotes laryngeal cancer progression via stabilizing DDX11 mRNA.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Laryngeal cancer (LC) is one of the malignant tumors affecting the head and neck region. 5-methylcytosine (m5C) is a common RNA modification that contributes to the carcinogenesis process. Aly/REF export factor (ALYREF), an m5C reader protein, exhibits dysregulation in various cancers, yet its role in LC remains unclear. To investigate this, we utilized CCK8 assays, colony formation, and flow cytometry for phenotypic analysis, while western blotting and real-time quantitative PCR were employed to assess ALYREF expression. The molecular mechanisms were explored using methylated RNA immunoprecipitation (MeRIP), RIP, dual-luciferase reporter assays, and protein stability experiments. Our data indicated that ALYREF was substantially overexpressed in LC tissues and cells. Silencing ALYREF resulted in reduced cell viability and proliferation in vitro, enhanced apoptosis, and suppressed tumor growth in vivo. Mechanistically, ALYREF interacted with DDX11 mRNA and enhanced its stability through NSUN2-mediated m5C modifications. Overall, our study suggested that ALYREF drove LC progression by stabilizing DDX11 mRNA. The findings provided novel insights into the role of ALYREF-induced m5C modifications in LC, opening up new perspectives for further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.